Nisen Perry 4

What Happened Nisen Perry, a director of Teva Pharmaceutical Industries Ltd. (TEVA), received a grant of 7,242 restricted share units (RSUs) on May 28, 2026. The RSUs were recorded as acquired at $0.00 (derivative award); the grant itself required no cash outlay. The RSUs vest on May 28, 2027 and each unit represents a contingent right to one ordinary share (or, at the committee’s option, the cash value of one ordinary share).

Key Details

• Transaction date: 2026-05-28; Filing date: 2026-06-01 (filed within two business days).
• Security: Restricted Share Units (derivative award) — 7,242 units granted at $0.00.
• Vesting: May 28, 2027 (per filing footnote).
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes: F1—Each RSU converts to one ordinary share or cash at settlement; F2—RSUs vest 5/28/2027; F3—Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 ordinary share).
• Transaction code: A (award/grant).

Context This is a compensation award (an RSU grant), not an open-market purchase or sale, so it reflects company compensation practices rather than an immediate insider market signal. The award is derivative and subject to future vesting and settlement conditions; it does not represent immediate ownership of tradable shares.